The year in brief Juli – SeptemberFinancial summary of the third quarter Net sales amounted to SEK 0 million (0,05 million). R&D costs amounted to SEK 10,9 million (8,8 million). Operating profit for the third quarter amounted to SEK...
Read MoreThird quarter in brief as well as the period 1 January – 30 September 2020 Net sales for the period (January to September) amounted to SEK 0,09 million (3,3 million), of which the third quarter contributed SEK 0,05 million...
Read MoreThird quarter in brief 1 July – 30 September 2019 Net sales for the period (January to September) amounted to SEK 3,3 Million (0,1 Million) of which the third quarter contributed SEK 0,2 Million (0,0 Million). R&D costs for...
Read MorePERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...
Read MorePERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...
Read MoreThe period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating income for the period amounted to SEK -15.8m (SEK...
Read MoreThe period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...
Read MoreJanuary 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read MoreAll figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read MoreAll figures relate to the Kancera Group unless otherwise specified. The 2011 comparison figures for operating income and income after financial items were affected by the release of negative goodwill of SEK 7m that arose in connection with the...
Read More